**Appendix C Reporting proforma for carcinomas of the oropharynx and nasopharynx**

|  |  |  |
| --- | --- | --- |
| Surname……………………… | Forenames………………….… | Date of birth…………..... Sex....... |
| Hospital………….……….…… | Hospital no……………….….... | NHS/CHI no…………….. |
| Date of receipt………….……. | Date of reporting………..…..... | Report no……………...... |
| Pathologist……….…………... | Surgeon………………….……. |  |

**Neoadjuvant therapy**

Information not provided □ Not administered □ Administered □   
Specify type: Chemotherapy □ Radiotherapy □ Chemoradiotherapy □ Targeted therapy □   
Immunotherapy □ specify if available ……………………………….

**Operative procedure (select all that apply)**

Not specified □ Resection, specify: □ ……………. Transoral laser microsurgical resection□

Transoral robotic surgical resection□Other □, specify…………………………

Biopsy (excisional, incisional) □, specify *……………………………*

Neck (lymph node) dissection[[1]](#footnote-1) □, specify …………………………  
Other □, specify…………………………..

**Specimens submitted (select all that apply)**    
Not specified □

Oropharynx □

Palatine tonsil □ Base of tongue/lingual tonsil □ Soft palate □ Uvula □   
Pharyngeal wall (posterior) □ Pharyngeal wall (lateral) □ Other □, specify…….……………

Nasopharynx □, specify if necessary ……………………………………

Other □, specify ………………………………………..

**Tumour site** **(select all that apply)**

Cannot be assessed □

Oropharynx □ Left □ Right □ Midline □ Laterality not specified □

Palatine tonsil □ Base of tongue/lingual tonsil □ Soft palate □ Uvula □   
Pharyngeal wall (posterior) □ Pharyngeal wall (lateral) □ Other □, specify …….………………

Nasopharynx □ Left □ Right □ Midline □ Laterality not specified □

Nasopharyngeal tonsils (adenoids) □ Fossa of Rosenmüller □ Lateral wall □

Other □, specify ……………………..

**Tumour dimensions**

Maximum tumour dimension (largest tumour) …………….mm

Additional dimensions (largest tumour) …………..mm x …………..mm

Cannot be assessed, specify …………………………

**Histological tumour type**

Salivary gland carcinoma □, specify type ………………………

Neuroendocrine carcinoma □, specify type …………………..

Other □, specify type ……………………………….

**Carcinomas of the oropharynx**

Squamous cell carcinoma, conventional □

Keratinising □ Non-keratinising □ Non-keratinising with maturation (‘partially keratinising’) □

Acantholytic squamous cell carcinoma □ Adenosquamous carcinoma □   
Basaloid squamous cell carcinoma □ Papillary squamous cell carcinoma □ Spindle cell carcinoma □ Verrucous cell carcinoma □ Lymphoepithelial carcinoma □

Other □, please state ………….

**Carcinomas of the nasopharynx**

Non-keratinising squamous cell carcinoma □

Differentiated □ Undifferentiated □

Keratinising squamous cell carcinoma □ Basaloid squamous cell carcinoma □

Nasopharyngeal papillary adenocarcinoma □ Cannot be assessed □, specify …………………….…….

**Histological tumour grade**

Not applicable □ GX: Cannot be assessed □ G1: Well differentiated □ G2: Moderately differentiated □

G3: Poorly differentiated □ Other □, specify …………… Cannot be assessed □, specify …………………

**Depth of invasion**

……………mm Not applicable □Cannot be assessed □, specify …………………

**Perineural invasion (oropharynx only)**

Not identified □Present□ Cannot be assessed □, specify …………………..

**Lymphovascular invasion (oropharynx only)**

Not identified □Present□ Not applicable □ Cannot be assessed □, specify …………………..

**Margin status**

Invasive carcinoma[[2]](#footnote-2) □

Involved □ specify margin(s) if possible ………………….

Not Involved □ Distance of tumour from closest margin ………… mm □ Distance not assessable □

Specify closest margin if possible ……………….

Carcinoma in situ/high-grade dysplasia3□

Involved □ specify margin(s) if possible ………………….

Not Involved □ Distance of tumour from closest margin ………… mm □ Distance not assessable □

Specify closest margin if possible …………………..   
Not applicable3 □ Cannot be assessed □, specify …………………………

**Co-existent pathology (select all that apply)**

None identified □

Dysplasia4 □

Mild □ Moderate □ Severe □

Focal □ Multifocal □ Discontinuous with the primary site □

Carcinoma in situ □

Focal □ Multifocal □ Discontinuous with the primary site □ Other □, specify ………………….

**Ancillary studies**

**Viral testing/viral tumour markers – oropharynx**

Not performed/unknown □ Performed □ (select all that apply)

P16 Immunohistochemistry □

Positive □

>70 nuclear and cytoplasmic staining of at least moderate to strong intensity □

Other criterion used □, specify ………………..

Negative □ Criteria used to determine results, specify …………………

High-risk HPV-specific testing □

DNA PCR □ Not identified □ Present □

DNA in situ hybridisation □ Not identified □ Present □

E6/E7 mRNA in situ hybridisation □ Not identified □ Present □

E6/E7 mRNA RTPCR □ Not identified □ Present □

**Viral testing/viral tumour markers – nasopharynx**

Not performed/unknown □ Performed □

EBV (EBER) in situ hybridisation – positive

EBV (EBER) in situ hybridisation – negative

**Other ancillary studies**

Not performed □ Performed □, specify …………………………………………........................

**Pathological staging (UICC TNM 8th edition)**

TNM Descriptors □ (only if applicable) specify:

**Primary tumour (pT)** …………………………………………………………

**P16 negative oropharynx** □

**Nasopharynx** □

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4Applicable for oropharyngeal surface mucosal disease only; not for tonsillar crypt epithelium.

1. If a neck dissection is submitted, then a separate dataset is used to record the information. [↑](#footnote-ref-1)
2. There is no clear morphologic distinction between invasive and in situ carcinoma for HPV-positive   
   oropharyngeal and EBV-positive nasopharyngeal carcinomas, so all carcinoma at margin should be included   
   in evaluation simply as ‘involved by carcinoma’.

   3Only applicable for HPV-negative oropharyngeal and EBV-negative nasopharyngeal tumours and for

   tonsillar surface disease. High-grade dysplasia is synonymous with moderate/severe dysplasia. [↑](#footnote-ref-2)